Compare Marriott International Inc (MAR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Moderna, Inc. — how do they compare? Marriott International Inc trades at $365 (market cap $96.76B), while Moderna, Inc. trades at $59.66 (market cap $23.60B). The key difference: Marriott International Inc is far larger — about 4.1× Moderna, Inc.'s market cap, and Marriott International Inc pays a 0.8% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MAR | MRNA | |
|---|---|---|
Market Cap | $96.76B | $23.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $81.80 |
52-Week Low | $255.35 | $22.36 |
Enterprise Value | $113.71B | $19.70B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $367.81, up 0.43% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $26.19B and net income of $2.60B, with a P/E of 38.42 and P/B of 443.63 indicating high valuation. Recent news includes strategic partnerships and the upcoming Q2 2026 earnings report on August 3, 2026.
The outlook is cautious due to high valuation and bearish technicals, but analyst consensus suggests a 5.6% upside to the $388.33 price target. Risks include rising debt-to-asset ratio (58.83% in 2025) and competitive pressures, while opportunities lie in travel demand growth and loyalty program strength.
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
